Masteron Enanthate (Drostanolone Enanthate) — Dosing, Cycles, Half-Life & Side Effects

Masteron Enanthate (Drostanolone Enanthate) is an injectable anabolic-androgenic steroid with a half-life of 7-10 days. Drostanolone enanthate — long-ester DHT-derivative variant of Masteron. Schering never marketed an enanthate ester clinically (Masteril was strictly propionate) — this is a PED-market-only ester variant; ALL PK and dosing values are extrapolated from propionate sibling + enanthate-ester kinetics. Non-17α-alkylated. Primary risks include strong HPTA suppression. This page is educational harm-reduction reference compiled from peer-reviewed literature — not medical advice, not an endorsement, not a recommendation to use. Consult a licensed clinician before any decision.

Quick Facts

ClassInjectables
Half-life7-10 days
Detection window90 days
AromatizationNo
HepatotoxicityNone
Suppression7/10
17α-alkylatedNo
Administrationinjectable

Typical Dosing Ranges

Common dose range: 400-600mg/week

Cycle length: 8-12 weeks

Time to steady state: ~35 days

Dose ranges are compiled from published pharmacokinetic studies and community-reported usage. Where a value is community-reported rather than clinically studied, this page and its structured data flag it. Lower end of any range is always the safer starting point.

Stacking Considerations

  • No structural stacking blockers. Standard harm-reduction rules apply: minimize total androgen load, minimize oral exposure, and monitor bloodwork.

PCT Requirements

  • This compound causes clinically meaningful HPTA suppression. Post-cycle therapy is recommended.
  • Depot clearance estimate: ~35 days post-last-dose before SERM start (5 × apparent depot half-life of 168h).
  • Never stack two SERMs. Extend a single SERM (tamoxifen OR enclomiphene/clomiphene) rather than combining.
  • Use the cycle planner to generate a full protocol based on your complete stack, not this compound alone.

Side Effect Profile

  • Longer to clear
  • Hair loss
  • Prostate effects
  • Expensive

Known Interactions

No compound-specific interactions are catalogued in the current matrix. This does not mean no risk exists — it means there is no curated pairwise entry.

Related compounds

Monitoring (Bloodwork & Vitals)

  • Comprehensive metabolic panel (baseline, mid-cycle, post-cycle)
  • Lipid panel (total cholesterol, HDL, LDL, triglycerides)
  • CBC (hemoglobin, hematocrit — watch for erythrocytosis)
  • Sex-hormone panel (Total T, Free T, Estradiol sensitive, SHBG, LH, FSH)
  • Blood pressure (weekly self-check; flag systolic >140 or diastolic >90)

Baseline bloodwork is recommended before any cycle. Discontinue if liver enzymes exceed 3× upper limit of normal or if hematocrit exceeds 54%.

Frequently Asked Questions

What is the half-life of Masteron Enanthate (Drostanolone Enanthate)?

Masteron Enanthate (Drostanolone Enanthate) has a half-life of approximately 7-10 days. Clearance estimate: 168h × 5 = 840h = 35 days. This figure is used to determine injection frequency (for esters) and post-cycle clearance timing.

What is the typical dose range for Masteron Enanthate (Drostanolone Enanthate)?

Commonly reported ranges for Masteron Enanthate (Drostanolone Enanthate): 400-600mg/week. Cycle length: 8-12 weeks. These are compiled from published studies and community-reported usage — individual response varies and lower end is always preferred.

Does Masteron Enanthate (Drostanolone Enanthate) suppress natural testosterone?

Masteron Enanthate (Drostanolone Enanthate) causes strong suppression of the HPTA axis (score 7/10). Post-cycle therapy (PCT) is recommended after use.

Does Masteron Enanthate (Drostanolone Enanthate) aromatize to estrogen?

Aromatization profile: No. Minimal to no aromatization expected, so aromatase inhibitors are not typically indicated for this compound alone.

What is Masteron Enanthate (Drostanolone Enanthate) typically used for?

Masteron Enanthate (Drostanolone Enanthate) is commonly used for: Cutting, Pre-competition, Long cycles. Intended-use context does not imply safety — every use case carries the same underlying pharmacological risks.

Citations

  1. Ester chemistry extrapolation. 2004. Clinical pharmacology reference — Half-life 7-10 days estimated from enanthate ester; enanthate form was never clinically studied (evidence grade C)
  2. Liu et al.. 2025. Substance Use & Misuse — AAS meta-analysis: SBP +12.43 mmHg (95% CI: 9.59-15.26), LDL-C +9.12 mg/dL (95% CI: 6.75-11.49)
  3. Hartgens F, Kuipers H. 2004. Sports Med — Enanthate-ester AAS depot kinetics 7-10 days based on testosterone-enanthate kinetics; drostanolone enanthate was never clinically marketed and lacks peer-reviewed PK data — extrapolation only
  4. Bennett MB, Helman P, Palmer P. 1975. S Afr Med J — Original Masteril (propionate) clinical breast-cancer use; enanthate variant has no clinical indication or RCT history — purely PED-market compound
  5. Niedfeldt MW. 2018. Curr Sports Med Rep — Non-17α-alkylated injectable AAS show minimal direct hepatotoxicity; supports 'None' rating (harmonized with propionate sibling)
  6. Mooradian AD, et al. Biological actions of androgens. Endocr Rev. 1987;8(1):1-28. PMID: 3549275
  7. Wilson JD. Androgens, androgen receptors, and male gender role behavior. Horm Behav. 2001. PMID: 11534997

Disclaimer

StackItSmart is an independent harm-reduction reference. The content above is compiled from peer-reviewed literature and is not medical advice, not an endorsement, and not a recommendation to use Masteron Enanthate (Drostanolone Enanthate). Performance-enhancing compounds carry legal, endocrine, cardiovascular, and hepatic risks. Consult a licensed clinician before any decision. StackItSmart does not provide sourcing, procurement, or dosing prescriptions.

Skip to main content